Derivates of the Antifungal Peptide Cm-p5 Inhibit Development of Candida auris Biofilms In Vitro

Antibiotics

Melaine Gonzalez-García¹  AnselmoJ. Otero-Gonzalez¹  Ludger Staendker²  Fidel Morales-Vicente³  Dennis Kubiczek⁴  Heinz Raber⁴  Frank Rosenau⁴ 

[1] Center for Protein Studies, Faculty of Biology, University of Havana, 25 Str. and I Str., La Habana 10400, Cuba;Core Facility for Functional Peptidomics, Ulm Peptide Pharmaceuticals (U-PEP), Faculty of Medicine, Ulm University, 89081 Ulm, Germany;General Chemistry Department, Faculty of Chemistry, University of Havana, Zapata y G, La Habana 10400, Cuba;Institute of Pharmaceutical Biotechnology, Ulm University, 89081 Ulm, Germany;

关键词: antimicrobial peptide;    Candida auris;    Candida albicans;    Candida parapsilosis;    peptide drug;   

DOI  :  10.3390/antibiotics9070363

来源: DOAJ

【 摘 要 】

Growth in biofilms as a fascinating and complex microbial lifestyle has become widely accepted as one of the key features of pathogenic microbes, to successfully express their full virulence potential and environmental persistence. This also increases the threat posed by Candida auris, which has a high intrinsic ability to persist on abiotic surfaces including those of surgical instruments and medical tubing. In a previous study, cyclic and helical-stabilized analogues of the antifungal peptide Cm-p5 were designed and synthetized, and proved to have increased activities against C. albicans and C. parapsilosis, but not against planktonic C. auris cells cultivated in suspension cultures. Here, we demonstrate, initially, that these derivatives, however, exhibited semi-inhibitory concentrations between 10–21 µg/mL toward C. auris biofilms. Maturated biofilms were also arrested between 71–97%. These novel biofilm inhibitors may open urgently needed new routes for the development of novel drugs and treatments for the next stage of fight against C. auris.

【 授权许可】

Unknown